Pila Pharma Q2: An Aspiring TRPV1 Platform Company - Redeye
Redeye comments on Pila Pharma’s Q2 report. Highlights from the quarter include receiving ODD for XEN-D0501 and the commencement of the toxicological studies with XEN-DIA. We fine-tune our valuation model.
ANNONS
Redeye comments on Pila Pharma’s Q2 report. Highlights from the quarter include receiving ODD for XEN-D0501 and the commencement of the toxicological studies with XEN-DIA. We fine-tune our valuation model.